CORRECTION article

Front. Oncol., 12 April 2023

Sec. Cancer Molecular Targets and Therapeutics

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1192526

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

  • 1. High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China

  • 2. University of Science and Technology of China, Hefei, China

  • 3. Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China

  • 4. High Magnetic Field Laboratory of Anhui Province, Hefei, China

  • 5. The CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science and Technology of China, Hefei, China

  • 6. The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

  • 7. Department of Pathology, Anhui Provincial Hospital, Hefei, China

  • 8. MOE Key Laboratory for Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China

Error in Figure/Table

In the published article, there was an error in Figure 3E as published. The representative picture of western blot bands of cleaved PARP1 of H446 cells were presented incorrectly. The corrected Figure 3E and its caption appear below.

Figure 3

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

small cell lung cancer, MYC paralog, PARP1, BET, DNA damage response

Citation

Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J and Lin W (2023) Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer. Front. Oncol. 13:1192526. doi: 10.3389/fonc.2023.1192526

Received

23 March 2023

Accepted

27 March 2023

Published

12 April 2023

Volume

13 - 2023

Edited and reviewed by

Shiv K. Gupta, Mayo Clinic, United States

Updates

Copyright

*Correspondence: Wenchu Lin,

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics